CURRICULUM VITAE EMORY UNIVERSITY SCHOOL OF MEDICINE

1,207 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,207
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

CURRICULUM VITAE EMORY UNIVERSITY SCHOOL OF MEDICINE

  1. 1. CURRICULUM VITAE EMORY UNIVERSITY SCHOOL OF MEDICINE Revised: 07-06-2007 Name: Dan Sorescu, MD Office Address: 1639 Pierce Drive, Division of Cardiology WMB Room 319, Atlanta, GA 30322 Telephone: 404-727-3364 (office); Heart Failure Clinic : 404-686-7885 Fax: 404-727-3585 E-mail Address: dsoresc@emory.edu Current Titles and Affiliations: Academic appointments: Primary appointments: July 1, 2003 Assistant Professor of Medicine: Emory University School of Medicine; tenure track Previous Academic and Professional Appointments: July 1, 2001-June 30, 2003 - Instructor in Medicine- Basic Science track, Emory University School of Medicine Licensures/Boards: Georgia Medical Board: 049344, expires 2009 United States Medical Licensing Examination 08-03-1995-valid indefinitely Specialty Boards: Board Certified in Internal Medicine 08/15/98-08/15/08 Board Certified in Cardiovascular Diseases 10/03-10/13 Education: 1982-1986 - High School of Mathematics and Physics; Baccalaureate; Alexandria, Romania 1988-1994 - Medical Degree: Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
  2. 2. Postgraduate Training: 09/1994-06/1995 - Medical Resident, Romania: volunteer, Carol Davila University, Bucharest, Romania-volunteer 07/01/1995-06/30/1998 - Residency in Internal Medicine, Beth Israel Medical Center, First Avenue at 16th Street (Albert Einstein College of Medicine), Program Director: Adrienne Fleckman, MD New York, NY 10003 07/01/1998-06/30/2001 – Vascular Biology Basic Science Research Fellow in the Division of Cardiology, Department of Medicine, Emory University School of Medicine, Mentor: Kathy K. Griendling, Atlanta, GA 30322 07/01/1998-06/30/03 - Fellowship in Cardiovascular Diseases; Cardiovascular Scientist Academic Program; Program Director: W. Robert Taylor, MD, PhD Honors and Awards: 06/1998 - Joseph H. Thompson Cardiology Fellow Research Award; Emory University 06/27/1998 - Dr. Stuart C. Alexander Award: “Most Outstanding Medical House Officer”- Beth Israel Medical Center; New York 06/08/2001- 2001 Angiotensin II Young Investigator Award for: “Localization of superoxide production, angiotensin II receptor type I and expression of the NADPH oxidase subunit p22phox in human coronary artery disease”, Philadelphia, Young Investigators Angiotensin II Symposium 07/2000-06/2001 - American Heart Association, Southeast Affiliate Postdoctoral Fellowship Award for the project: “The role of oxidative systems in angiotensin II induced-cardiac hypertrophy” 07/1998-06/2000 - American Heart Association, Southeast Affiliate Postdoctoral Fellowship Award for the project: “The role of oxidative systems in angiotensin II induced-cardiac hypertrophy” Society Memberships: 1998-present - American College of Cardiology 2005- Fellow of American College of Cardiology 04/2000-present - Council of Atherosclerosis, Thrombosis and Vascular Biology, American Heart Association 03/2000-present - Council of Clinical Cardiology, American Heart Association 09/1999-present - Oxygen Society of Free Radicals 09/1999-present - International Society of Free Radicals Research 07/2003-present - Heart Failure Society
  3. 3. Organization of National or International Conferences: (Title, conference, year(s)): 2001 - Co-Chair, (Session Moderator) “Oxidative stress in Endothelial Cells”, American Heart Association, National Scientific Sessions. 2004 - Co-Chair (Session Moderator) “Consequences of Cardiac Oxidant Stress” American Heart Association National Scientific Session 2005- Co-Chair (Session Moderator) “NADPH oxidase and the cardiovascular system” American Heart Association National Scientific Session Research focus: Basic Science: I am currently studying the role of oxidative systems in the development of cardiac hypertrophy and progression to heart failure and aging-associated heart failure. Clinical and translational heart failure: I am studying the role of echocardiography in detection of dyssynchrony in heart failure using a canine model of heart failure with dyssynchrony. Research interests in tissue Doppler and strain-based echocardiography to identify patients candidates for CRT, especially in patients with narrow QRS and left ventricular systolic dysfunction and study of devices to help manage volume status of patients with class III-IV NYHA heart failure (Opti-vol, Chronicle BiV-ICD). Grant Support: (Investigator status (P.1., Co-P.L), source, title, award type, amount, year(s)) a. Active Grant Support: P.I. (principal investigator) for American Heart Association, Grant-In-Aid (Southeast Affiliate) for the project: “Nox4 Regulation of Fibrotic Gene Expression in Murine Cardiac Fibroblasts” July 1, 2007- June 30, 2009: $77,000/ year. b. Past Active support: P.I. (principal investigator) for American Heart Association, National Scientist Development Grant for the project: “The role of novel gp91phox homologues in Angiotensin II- induced cardiac fibrosis” July 1, 2003- June 30, 2007: $65,000/ year. P.I. American Federation of Aging, National “Role of Nox4 in cardiac senescence” July 1, 2005- June 30, 2007: $30,000/year
  4. 4. P.I. Emory University Research grant “Nox4 in TGF-!1 -induced cardiac hypertrophy and fibrosis” July 1, 2005-June 30, 2006: $30,000/year Co-Investigator for NIH grant: “ACTION- A CHF Trial Investigating Outcomes of Exercise”, $196,224/year, 09/30/2002-07/31/2006 American Heart Association, Southeast Affiliate Postdoctoral Fellowship Award 1. July 1, 1998-June 30, 2000: $25,000/year 2. July 1. 2000-June 30, 2001: $30,000 Clinical Service Contributions: June 27, 1998 - Dr. Stuart C. Alexander Award: “Most Outstanding Medical House Officer”- Beth Israel Medical Center; New York, Transthoracic, stress and transesophageal echocardiography reading, lectures and training of clinical cardiology fellows at Emory University. Supervision of the General Cardiology inpatient service and Chronic Heart Failure Clinic at Emory-Crawford Long Hospital Supervision/rounding with a team composed of two internal medicine residents, one-two medical student and two cardiology fellows in CCU and in-patient cardiology consultation services at Emory-Crawford Long Hospital (4-6 rotations/year). Preceptor-Clinical Methods for second year medical students, 6 sessions per semester; spring and fall 2004; spring 2005, fall 2006 Heart Failure Clinic (Center for Heart Failure Therapy at Emory-Crawford Long Hospital) one day a week- management of patients with class III-IV heart failure, management of CRT-D post- implant (A-V, V-V optimization of biventricular pacemakers), and volume status using Opti-vol, Chronicle BiV/ICD devices. Supervisory teaching (in basic science laboratory at Emory University, WMB Room 309) Ursula Haider, PhD, 2002, visiting student, University of Munich, Germany Jooyoung Julia Shin, M.D.-postdoctoral research fellow basic science. Currently, Assistant Professor of Medicine- Center for Advanced Cardiac Therapy, Montefiore Medical Center Jeffrey Sacks, undergraduate student (Washington University, St Louis), summer 2004 Anum Niazi, undergraduate student (Vanderbilt University, Nashville), summer 2004 Patrick Phelan, second year medical student (Emory University), winter-spring 2005.
  5. 5. Daniel Sims, second year medical resident (currently chief resident at Emory currently cardiology fellow at Columbia University (New York) - elective molecular cardiology rotation October-November 2005. Yvonne Schilder, PhD student, Department of Pharmacognosy, University of Vienna, april –june 2006 Calin Chiribau, PhD, postdoctoral fellow, fall 2005-present. Ioan Cucoranu, MD, postdoctoral research fellow 2003- present Sofya Tokman, as 3rd and 4th year medical student, Emory University, spring 2007-present (also supervised on clinical wards). Lectureship, Seminar Invitations, and Visiting Professorship: “The effect of carvedilol on morbidity and mortality in patients with chronic heart failure” Journal Club, Beth Israel Medical Center, New York, September 18, 1996 “Sorcin and coupling of excitation with contraction in cardiac myocyte” Resident Lecture, Beth Israel Medical Center, New York , January 15, 1997 “Cardiac remodeling and the progression to end stage heart failure” Resident Lecture, Beth Israel Medical Center, New York, May 28, 1998 “Reactive oxygen species and cell cycle progression in vascular smooth muscle cells” Fifth Annual Emory University Cardiology Fellowship Symposium, Atlanta, May 10, 1999 “In situ detection of superoxide in human coronary artery” Joint Annual Emory University-University of Alabama Oxygen Free Radicals in Cardiovascular Diseases Research Symposium December 16, 1999 “Localization of superoxide production and expression of the NAD(P)H oxidase p22phox subunit in human coronary artery” Sixth Annual Emory University Cardiology Fellowship Symposium, Atlanta, May 09, 2000 “Molecular remodeling in progression of end stage heart failure” Lecture for Emory Cardiology Fellowship Curriculum, Atlanta September 29, 2000 “Correlation of in situ detection of superoxide with the expression of NAD(P)H oxidase subunits in human coronary arteries” Seventh Annual Emory University Cardiology Fellowship Symposium, Atlanta, May 17, 2001 NADPH Oxidases in Cardiovascular Disease, Basic Science Seminar, Emory University Hospital, Atlanta, April 09, 2004
  6. 6. “Optimization of Heart Failure Therapy” Symposium of Heart Failure Therapy, Crawford Long Hospital, Atlanta April 14, 2004 “Cardiac Resynchronization and Implantable Defibrillator Therapy for Heart Failure” Atlanta’s Heart Failure Symposium May 8, 2004 “Role of Nox homologues in cardiac fibrosis”, Vascular Biology Seminar, Division of Cardiology, Emory University, Atlanta May 15, 2004 “Coronary Artery Disease and Prevention”: Emory University Board Review in Internal Medicine Atlanta, July 12 2004 “Management of acute heart failure” CME organized by Emory Heart Center at West Georgia Family Medicine; Villa Rica, Georgia, August 10, 2004 “Patient selection for cardiac resynchronization therapy” Cardiac Resynchronization Live Hosted by the Carlyle Fraser Heart Center at Crawford Long Hospital; Atlanta; August 13, 2004 “Management of Acute Heart Failure”- Emory-Crawford Long Hospital Grand Rounds October 1, 2004, Atlanta “Current Management Strategies in Heart Failure”- Grady Memorial Hospital Grand Rounds, October 21, 2004, Atlanta “Is treament of hypertension essentially the same for all patients or it varies based on gender, race and age?” Hypertension session of Emory Primary Care Symposium, November 12, 2004, Atlanta “Echocardiography in heart failure”, Emory University Cardiology Fellows curriculum, Crawford Long Hospital, November 18, 2004, Atlanta, “Echocardiographic estimation of cardiac filling pressures”, Emory University Cardiology Fellows curriculum, Crawford Long Hospital, January 06, 2005, Atlanta “Pharmacological approach for heart failure therapy”, part 1, Emory University Cardiology Fellows curriculum, February 16, 2005, Atlanta “New Insights into Pharmacologic Therapies for Chronic Heart Failure”, Fellows Symposium on Heart Failure organized by Emory University, February 18-20, 2005, Miami “Pharmacological approach for heart failure therapy-genetics determinants”, part 2, Emory University Cardiology Fellows curriculum, February 23, 2005, Atlanta “Diastology”, Emory University Cardiology Fellows curriculum, Crawford Long Hospital, March 15, 2005, Atlanta
  7. 7. “Management of Acute Decompensated Heart Failure”, Grand Rounds, Brunswick General Hospital, Brunswick, GA, April 29, 2005 “B-type Natriuretic Peptide and Acute Decompensated Heart Failure - from bench to bedside”, Basic Science Seminar, Division of Cardiology Emory University Hospital, Atlanta, May 20, 2005 “Role of angiotensin receptor blockers in heart failure”, Grand Rounds, Dekalb Medical Center, Atlanta, June 10, 2005 “Echocardiographic approach of Constrictive pericarditis versus Restrictive cardiomyopathy” Emory University Cardiology Fellows curriculum, Emory University Hospital, June 21, 2005, Atlanta “Coronary Artery Disease and Prevention” Emory University Board Review in Internal Medicine Atlanta, August 1, 2004, July 31, 2005 and August 3, 2006 “Echocardiographic estimation of cardiac filling pressures and diastolic dysfunction” American Society of echocardiography- Atlanta Chapter, Piedmont Hospital, August 1, 2005 “Pharmacologic therapy for acute and chronic heart failure”- a series of 4 lectures for cardiology fellows’ curriculum: January- February 2006, WMB Room 319, Emory University “Echocardiography: diastology, restrictive cardiomyopathy, constrictive pericarditis, cardiac tamponade”- three lectures for cardiology fellows: Emory University: January-february 2006; “Acute decompensated heart failure: “How to “dry out” without adverse events”- Fluid management in acute heart failure Symposium organized by Emory University, Division of Cardiology, Heart failure (director Andrew Smith), Atlanta, GA February 25, 2006 “Coronary Artery Disease and Prevention” Emory University Board Review in Internal Medicine Atlanta, July 31, 2006 “Acute decompensated heart failure”- a series of 3 lectures for cardiology fellows’ curriculum: September-October 2006, Emory University, Atlanta "Cardio-renal syndrome and heart failure" Internal Medicine Grand Rounds, October 24, 2006, Grady Hospital, Atlanta. "Case studies in Hypertension" Emory Primary Care Symposium, October 24, 2006, Intercontinental Hotel, Atlanta. “NADPH oxidases and cardiac remodeling”, Vascular Biology Seminar, Division of Cardiology, Emory University, Atlanta, GA November 27, 2006 “Diastolic dysfunction for cardiac anesthesiologist” Emory University, Atlanta, October 1, 2006;
  8. 8. “Echocardiographic diagnosis of restrictive cardiomyopathy and constrictive pericarditis”- cardiology fellow curriculum, Emory University, Atlanta, November 22, 2006 “Case studies in heart failure”- cardiology fellows curriculum, CLH, February 8, 2007 “Management of volume overload in acutely decompensated heart failure with diuretics and ultrafiltration”- Cardiology- Cardiothoracic surgery grand rounds, CLH, February 21, 2007 “TGF-!1 and aortic aneurysms-from bench to bedside”- Journal club cardiology fellows, February 27, 2007, Atlanta. Invitations to National or International Conferences: 1. “Reactive oxygen species and cell cycle progression in vascular smooth muscle cells.” Astra Cardiovascular Young Investigator Award, Banff, Canada, October 31, 1999 2. “Reactive oxygen species and cell cycle progression of vascular smooth muscle cells.” The 72nd Scientific Sessions of American Heart Association, Atlanta, November 7-10, 1999 3. “Requirement of reactive oxygen species for cell cycle progression in vascular smooth muscle cells.” Oxygen Society Meeting New Orleans, November 15, 1999 4. “Localization of superoxide production and expression of the NAD(P)H oxidase subunit p22phox in human coronary artery.” The 73nd Scientific Sessions 2000 of American Heart Association, New Orleans, November 12-15, 2000 5. “Hydrogen peroxide induces arrest of vascular smooth muscle cells in late G1: role of cyclin A and cell cycle inhibitors p53 and p21.” The 73nd Scientific Sessions 2000 of American Heart Association, New Orleans, November 12-15, 2000 6. “Expression of the NAD(P)H oxidase subunits in human coronary arteries.” The 74nd Scientific Sessions of American Heart Association, Annaheim, California, November 12, 2001 7. “Correlation of in situ detection of superoxide with the expression of angiotensin II type I receptor and NAD(P)H oxidase subunits in human coronary arteries.” Young investigators Angiotensin II Symposium, Philadelphia, June 07, 2001 8. “NAD(P)H oxidases and human coronary artery disease”. Australian Health & Medical Research Congress, Melbourne, Australia. Invited as international speaker at the Symposium: “Oxidases in Cardiovascular Diseases”, November 25-29, 2002 9. “Nox 4-based NAD(P)H oxidase mediates TGF- !1-induced differentiation of human cardiac fibroblasts into myofibroblasts”, The 77nd Scientific Sessions of American Heart Association, New Orleans, LA, November 12, 2004
  9. 9. 10. “Deletion of p47phox Subunit of NADPH Oxidase in Mice Causes Severe Cardiac Fibrosis in Response to Angiotensin II”- The 78nd Scientific Sessions of American Heart Association, Dallas, TX, November 12, 2005 11. “Redox signaling and NADPH oxidases in cardiovascular disease: theory and practice” a course of 10 lectures for PhD students in Pharmacy, department of Pharmakognosy, University of Vienna, Austria- Visiting Professor June 5-30, 2006; invited by Professor Verena Dirsch (Chair of Department of Pharmakognosy, University of Vienna, Austria). 12. “Nox4 Mediates Cardiac Fibrosis while p47phox-based Nox2 is required for the inflammatory response to Angiotensin II in murine cardiac fibroblasts” - American Heart Scientific Sessions November 2006, Circulation 2006 Grant reviewer for: 2005-2007 American Heart Association, Southern and Ohio Valley Research Consortium Integrative Cardiac Biology/Regulation Vascular Biology. 2005-2007 Emory University Research Committee. 2004 and 2007, abstract reviewer for American Heart Association, National Meeting Manuscript reviewer for 2001 - Antioxidants and Redox Signaling 2002 - American Journal of Physiology: Cell Physiology 2002 - Hypertension 2003 – Circulation 2003 – Circulation Research 2003 – Molecular Pharmacology 2003 – Kidney International 2003 – Cancer Letters 2003 – Journal of Cardiac Failure 2004 – European Heart Journal 2006 – Biochemica and Biophysica Acta: Molecular Basis of Disease 2006 – American Journal of Cardiology Bibliography: (Chronologic order: authors, year, title, journal, volume, complete page numbers) a. Published and accepted research articles (clinical, basic science, other) in refereed journals: 1. Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, Lambeth JD. Cell transformation by the superoxide-generating oxidase Mox 1. Nature 1999; 401:79-82.
  10. 10. 2. Sorescu D, Somers MJ, Lassègue B, Grant SL, Harisson DG, Griendling KK. Electron spin resonance characterization of the NAD(P)H oxidase in vascular smooth muscle cells. Free Radicals Biology and Medicine 2001;30:603-612. 3. Scott NA, Crocker IR, Yin Q, Sorescu D, Wilcox JN, and Griendling KK. Inhibition of vascular cell growth by x-ray irradiation: Comparison with gamma radiation and mechanism of action. Int J Radiat Oncol Biol Phys 2001;50:485-93. 4. Lassegue B, Sorescu D, Scozs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, Griendling KK. Novel gp91phox homologues in vascular smooth muscle cells: nox1 mediates angiotensin ii-induced superoxide formation and redox sensitive signaling pathways. Circulation Research 2001;88:888-94. 5. Szöcs K, Lassegue B, Sorescu D, Lambeth JD, Griendling KK. Upregulation of gp91phox homologs in rat carotid injury. Arterioscler Thromb Vasc Biol. 2002; 1:21-7. 6. Sorescu D, Weiss D, Lassègue B, Clempus RE, Szöcs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, and Griendling KK. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002;105:1429-35. 7. Sorescu D, Deshpande NN, Ushio-Fukai M, Akers M, Yin Q, Griendling KK. Mechanism of hydrogen peroxide-induced cell cycle arrest in vascular smooth muscle. Antioxid Redox Signal 2002; 4:845-54 8. Haider UGB, Sorescu D, Griendling KK, Vollmar A, Dirsch VM. Resveratrol suppresses Angiotensin II-induced Akt/Protein Kinase B as well as p70 S6 Kinase Phosphorylation and Subsequent Hypertrophy in Rat Aortic Smooth Muscle Cells. Molecular Pharmacology 2002; 62:772-7 9. Sorescu D, Turk RJ, Cain M, Lerakis S, Clinical and transthoracic echocardiographic predictors of abnormal transesophageal findings in patients with suspected cardiac source of embolism. American Journal of Medical Sciences, 2003 10) Haider UGB, Sorescu D, Griendling KK, Vollmar A, Dirsch VM. Resveratrol increases serine15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells. Molecular Pharmacology, 2003 Apr;63(4):925-32. 11) Haider UG, Roos TU, Kontaridis MI, Neel BG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM. Resveratrol inhibits angiotensin II- and EGF-mediated Akt activation - role of Gab1 and Shp2. Molecular Pharmacology, 2005 Jul;68(1):41-8. 12) Cucoranu I, Clempus RE, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D. “Nox4 mediates TGF-!1-induced differentiation of cardiac fibroblasts into myofibroblasts”- Circulation Research- 2005 Oct 28;97(9):900-7
  11. 11. 13) Haider UG, Roos TU, Kontaridis MI, Neel BG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM. “Resveratrol inhibits angiotensin II- and epidermal growth factor-mediated Akt activation: role of Gab1 and Shp2”. Mol Pharmacol. 2005 Jul;68(1):41-8. Epub 2005 Apr 22. 14) Amar D. Patel, Walter L. Few III, Eugen Ivan, Dan Sorescu, Tarek Helmy. “Diagnostic modalities for the evaluation of anomalous left main coronary arteries” Cardiovascular Revascularization Medicine 6 (2005) 32–35. 15) Sorescu D. “Smad3 Mediates Angiotensin II– and TGF-!1–induced vascular fibrosis-Smad3 thickens the plot” ”- Circulation Research- 2006 Mar 2006 16) Jin Suo, Dardo E. Ferrara, Dan Sorescu, Robert E. Guldberg, W. Robert Taylor, and Don P. Giddens. Hemodynamic “Shear Stresses in Mouse and Human Aortas: Implications for Atherogenesis”. ATVB, November 22 2006 17) Roza E. Clempus, Dan Sorescu, Anna E. Dikalova, Lily Pounkova, Patricia Jo, Bernard Lassègue, and Kathy K. Griendling. “Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype”- ATVB, November 2 2006. 18) Arita T, Sorescu GP, Schuler BT, Schmarkey LS, Merlino JD, Vinten-Johansen J, Leon AR, Martin RP, Sorescu D. “Speckle-tracking strain echocardiography for detecting cardiac dyssynchrony in a canine model of dyssynchrony and heart failure”. Am J Physiol Heart Circ Physiol. 2007 Apr 20; b. Manuscripts submitted: c. Review articles: 1. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circulation Research 2000; 86:494-501 (Review). 2. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arteriosclerosis Thrombosis and Vascular Biology 2000; 10: 2175-83 (Review). 3. Sorescu D, Szöcs K, Griendling KK. NAD(P)H Oxidases and their particular relevance to Atherosclerosis. Trends in Cardiovascular Medicine 2001; 11:124-31 (Review). 4. Weiss D, Sorescu D, Taylor WR: Angiotensin II and atherosclerosis: American Journal of Cardiology. 2001; 87:25C-32C (Review). 5. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congestive Heart Failure. 2002;8:132-40 (Review).
  12. 12. Published abstracts: 1) Sorescu D, Somers MJ, Lassegue B, Grant SL, Griendling KK. A biochemical characterization of vascular myocyte NAD(P)H oxidase using electron spin resonance. Free Radical Biology and Medicine, 1999; 27: S24. 2) Lassegue B, Sorescu D, Chung AB, Yin Q, Despahne N, Lambeth JD, Griendling.KK. p65 Mox, a Novel Gp91-Phox analogue, participates in superoxide generation and cellular proliferation in vascular smooth muscle cells. Circulation 1999; 100: 224. 3) Chung AB, Deshpande N, Lassegue B, Yin Q, Sorescu D, Alexander RW, Griendling KK. Cloning and characterization of a novel redox-sensitive transcription factor form aortic smooth muscle cells that binds to the promoter of monocyte chemotactic protein-1 Circulation 1999; 100: 228. 4) Sorescu D, Lassegue B,.Chung AB, Grant SL, Griendling KK. Reactive oxygen species and cell cycle progression of vascular smooth muscle cells. Circulation 1999; 100: 2523. 5) Deshpande NN, Sorescu D, Ushio-Fukai M, Yin Q, Akers M, Griendling KK. Hydrogen peroxide induces arrest of vascular smooth muscle cells in late G1; role of cyclin A and cell cycle inhibitors p53 and p21. Circulation, 2000;102:II-167. 6) Sorescu D, Weiss D, Vega JD, Griendling KK, Taylor WR. Localization of superoxide production and expression of the NADPH oxidase subunit p22phox in human coronary artery Circulation 2000; 102: 1475. 7) Szocs K, Lassegue B, Sorescu D, Miller FJ, Lambeth JD, Griendling KK. Nox-1, a novel gp91 phox homologue, is upregulated in restenosis following balloon injury. Circulation 2000; 102:1484. 8) Vlastos GA; Goldschmidt ME; Sorescu D; Taylor WR. Cyclic strain stimulates intracellular superoxide production in vascular smooth muscle cells. Biomedical Engineering Society Annual Meeting October 12-14, 2000 Seattle, Washington USA. 9) Haider UGB, Sorescu D, Griendling KK, Vollmar A, Dirsch VM. Resveratrol inhibits proliferation and cell cycle progression of rat aortic vascular smooth muscle cells-involvment of Akt kinase? Free Radical Biology and Medicine, 2001; 33:S24. 10) Sorescu D, Weiss D, Lassègue B, Szöcs K, Vega JD, Taylor WR, Griendling KK. Expression of the NAD(P)H oxidase subunits in human coronary arteries. Circulation 2001; 104: 192. 11) Szocs K, Lassegue B, Valppu L, Hilenski LL, Sorescu D, Lambeth JD, Griendling KK. Differential upregulation of nox1, nox4 and p22phox following balloon injury: evidence for diverse functions of vascular NAD(P)H oxidases in restenosis. Circulation 2001; 104: 193.
  13. 13. 12) Wyche KE, Griendling KK, Dikalov SI, Austin H, Sorescu D, Harrison DG, Zafari AM. The C242T p22phox Polymorphism of the NADPH oxidase is associated with reduced superoxide production in human neutrophils. Circulation 2001; 104:193. 13) Seshiah PN, Sorescu D, Dikalov S, Griendling KK. Upstream mediators of angiotensin II activation of the vascular smooth muscle NAD(P)H oxidase. Circulation 2001; 104: 196. 14) Cucoranu I, Clempus RE, Sorescu D, Nox4-based NAD(P)H oxidase mediates TGF- !1- induced differentiation of human cardiac fibroblasts into myofibroblasts, Circulation 2004; 110, 748, p157 15) Roza E Clempus, Dan Sorescu, Bernard Lassegue, Anna Dikalova, Kathy K Griendling, Nox4-derived Reactive Oxygen Species are required for the Differentiation of Vascular Smooth Muscle Cells ; Circulation 2004; 110, 745, p157 16) Shin JJ, Cucoranu I, Sorescu GP, Griendling KK, Sorescu D: “Deletion of p47phox Subunit of NADPH Oxidase in Mice Causes Severe Cardiac Fibrosis in Response to Angiotensin II”- Circulation 2005; 112, 17, p 321 17) Takeshi Arita, George P. Sorescu, Brian T. Schuler, Laura S. Schmarkey, John D. Merlino Randolph P. Martin, Jacob Vinten-Johansen, Angel R.Leon, Dan Sorescu: “Comparison of various dyssynchrony parameters of echocardiography in the canine model of heart failure with dyssynchrony”. JACC 2006; 47; 4; 118A 18) Takeshi Arita, John D. Merlino, Maria A. Pernetz, Sharon Howell, Mikhael El-Chami, Stamatios Lerakis, Dan Sorescu, Stephen D. Clements, and Randolph P. Martin: “Assessment of longitudinal, radial and circumferential dyssynchrony using speckle tracking and tissue Doppler in patients with systolic heart failure and narrow QRS”. JACC 2006; 47; 4; 134A 19) Takeshi Arita, George P Sorescu, Brian T Schuler, Laura S Schmarkey, John D. Merllino, Jacob Vinten-Johansen, Randolph P Martin, Angel R Leon, Dan Sorescu “Speckle tracking-derived radial and circumferential strain are superior to color tissue Doppler-derived longitudinal velocity to detect mechanical dyssynchrony in a canine model of heart failure with dyssynchrony” Journal of American Society of Echocardiography june 2006 (oral presentation of ASE 2006) 20) Takeshi Arita, Brandon Fornwalt, Dean Notabartolo, Maria A Pernetz, Stamatios Lerakis, Stephens D Clements, Dan Sorescu, John D Merlino, Randolph P Martin, Angel R Leon “Novel assessment of cardiac dyssynchrony using variance of dyssynchrony vector on tissue Doppler imaging to predict reverse remodeling” Journal of American Society of Echocardiography june 2006 (oral presentation of ASE 2006). 21) Takeshi Arita, Brandon Fornwalt, George P Sorescu, Brian T Schuler, Patrick Whalen, Angel Leon, John Merlino, Randolph Martin, Dan Sorescu, “Systolic Dyssynchrony is present in heart failure with narrow or wide QRS, while diastolic dyssynchrony is present only in heart failure with wide QRS in a canine model of heart Failure” - American Heart Scientific Sessions November
  14. 14. 2006, Circulation, 2006 (oral presentation at AHA). 22) Ioan Cucoranu, Calin B Chiribau, Roza E Clempus, Brandon Kitchel, George P Sorescu, Kathy K Griendling, Dan Sorescu “Nox4 Mediates Cardiac Fibrosis while p47phox-based Nox2 is required for the inflammatory response to Angiotensin II in murine cardiac fibroblasts” - American Heart Scientific Sessions November 2006, Circulation 2006 23) S. Patrick Whalen, Brian T. Schuler, George Sorescu, Laura Schmarkey, Jakob Vinten- Johansen, Jonathan Langberg, Angel Leon, Dan Sorescu Transmuscular Lead Placement - A new option for biventricular (BiV) pacing - American Heart Scientific Sessions November 2006, Circulation 2006

×